Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Filings indexed 3,397 across all filing types
Latest filing 2026-05-18 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 90% confidence The document is an RNS announcement titled “Transaction by Person Discharging Managerial Responsibilities.” It details an award of ordinary shares vesting to the CEO, including volumes, prices, dates, and references the EU Market Abuse Regulation. This is a report of insider share transactions by a company director. Therefore, it is classified as a Director’s Dealing.
2026-05-18 English
DIRECTOR/PDMR SHAREHOLDING
Regulatory Filings
2026-05-18 English
BAXFENDY APPROVED IN THE US FOR HYPERTENSION
Regulatory Filings
2026-05-18 English
ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS
Regulatory Filings
2026-05-18 English
Enhertu approved in two HER2+ early BC settings
Regulatory Filings Classification · 92% confidence The document is a press release distributed via RNS (Regulatory News Service) with an RNS number header, announcing FDA approvals for new drug indications. It contains no financial statements, no investor presentation slides, no management discussion, and no meeting materials. It is a generic regulatory announcement of corporate news, fitting the fallback category for miscellaneous regulatory filings.
2026-05-18 English
Baxfendy approved in the US for hypertension
Regulatory Filings Classification · 87% confidence The document is an RNS press release announcing FDA approval of a new drug (Baxfendy) by AstraZeneca, distributed via the UK’s Regulatory News Service. It is a corporate news release, not a financial report, earnings release, management change, or other specific filing type, so it falls under the general Regulatory Filings (RNS) category.
2026-05-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.